Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Notes Payables (2022 - 2024)

Mereo BioPharma (MREO) has disclosed Notes Payables for 2 consecutive years, with $5.5 million as the latest value for Q4 2024.

  • Quarterly Notes Payables changed N/A to $5.5 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $5.5 million through Dec 2024, changed N/A year-over-year, with the annual reading at $5.5 million for FY2024, N/A changed from the prior year.
  • Notes Payables for Q4 2024 was $5.5 million at Mereo BioPharma, roughly flat from $5.6 million in the prior quarter.
  • The five-year high for Notes Payables was $13.3 million in Q4 2022, with the low at $4.6 million in Q1 2024.